Immediate Impact
1 standout
Citing Papers
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
2021 Standout
Works of Amanda Carbonell being referenced
Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Amanda Carbonell | 33 | 2 | 15 | 19 | 2 | 37 | |
| Elisabeth Medeiros | 22 | 1 | 27 | 27 | 4 | 47 | |
| Mohammad A Abdulrazzak | 20 | 2 | 14 | 10 | 3 | 24 | |
| Paul Emile Labeyrie | 52 | 2 | 14 | 7 | 2 | 54 | |
| Annemarie Brandhofe | 14 | 2 | 12 | 12 | 4 | 30 | |
| Anne Laure Derelle | 17 | 1 | 19 | 22 | 3 | 33 | |
| Timothy Malisch | 41 | 2 | 14 | 10 | 4 | 47 | |
| Noah Beadell | 18 | 1 | 11 | 21 | 3 | 37 | |
| C Brooks | 30 | 3 | 25 | 6 | 4 | 42 | |
| Colleen Lechtenberg | 20 | 2 | 10 | 17 | 2 | 36 | |
| Gregory Van der Steen | 38 | 3 | 10 | 12 | 3 | 48 |
All Works
Login with ORCID to disown or claim papers
Loading papers...